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1. Introduction 
Diabetes mellitus is a widespread metabolic disease characterized by hyperglycemia and 
associated with severe complications, including cardiovascular disease and dyslipidemia. 
The cardiovascular risk is considerably increased in diabetic patients, and novel 
cardioprotective strategies are sought that could target both diabetic and cardiovascular 
outcomes. L-carnitine is a conditionally essential amino acid that plays an important role in 
cellular energy metabolism. Initial pharmacological studies suggest that preconditioning-
like manipulation of substrate metabolism through the regulation of L-carnitine homeostasis 
could be an effective approach for the prevention of myocardial infarction and the treatment 
of heart failure, especially for patients with type 2 diabetes. Contradictory data exist 
concerning the pharmacological outcomes of L-carnitine treatment. It is known that L-
carnitine supplementation is beneficial and increases overall glucose utilisation in animals 
and humans.  
Interestingly, a state of limited L-carnitine availability also induces compensatory 
mechanisms that alter the pathways of energy metabolism. In some experimental studies, a 
decrease in L-carnitine concentration was achieved by the administration of 3-(2,2,2-
trimethylhydrazinium)-propionate (mildronate). In addition to its cardioprotective and anti-
atherosclerotic effects, it was shown recently that mildronate, by decreasing L-carnitine 
concentration, decreases fed and fasted blood glucose concentrations and prevents diabetic 
complications in an experimental model of type 2 diabetes, Goto-Kakizaki (GK) rats, and an 
obesity model using Zucker rats. Recently presented mildronate-induced gene expression 
profiles suggest the peroxisome proliferator-activated receptors (PPARs) as possible nuclear 
factors underlying the effects of mildronate and decreased L-carnitine availability on FA 
metabolism. The effects of mildronate might depend on dosing and the length of treatment, 
which could differentially compensate for the decreased L-carnitine availability and thereby 
inhibit FA metabolism by activating glucose utilisation. Thus, it is possible that a limited 
availability of tissue L-carnitine might improve the metabolic flexibility of muscle tissues 
and enhance the preconditioning-like adaptive responses.  
2. Effects of L-carnitine 
L-carnitine is a conditionally essential amino acid that plays an important role in cellular 
energy metabolism. In heart and skeletal muscle, L-carnitine aids the translocation of long-
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chain FA into the mitochondria for subsequent beta-oxidation, which is a major energy 
source in muscle cells. L-carnitine is absorbed from dietary products and biosynthesised 
from lysine and methionine; its excretion is efficiently regulated by renal re-absorption. The 
physiological range of L-carnitine concentrations in various tissues is maintained by 
complex transporter systems. 
2.1 L-carnitine in pathways of energy metabolism 
The homeostasis of cellular energy metabolism relies on the availability of two major 
sources of substrates: FA and carbohydrates. Through catabolic processes, both substrates 
provide a metabolite, acetyl coenzyme A (acetyl-CoA), which further undergoes oxidation 
in the mitochondrial machinery to provide cellular metabolism with adenosine-5'-
triphosphate (ATP) molecules, the "molecular unit of currency" of intracellular energy 
transfer (Koves et al., 2008a). The role of L-carnitine in regulating cellular energy 
metabolism is schematically summarised in Fig. 1. First, L-carnitine is a substrate of the 
enzyme L-carnitine palmitoyltransferase-1 (CPT I), which catalyses the rate-limiting reaction 
in the transfer of FA into the mitochondria (Kuhajda et al., 2007). The key mechanism for 
regulation of CPT I activity is allosteric inhibition by malonyl CoA (Cuthbert et al., 2005). 
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Fig. 1. The cellular pathways of energy metabolism 
In the CPT I-catalysed reaction, L-carnitine and acyl-CoA-activated long-chain FA interact to 
form long-chain acyl-L-carnitine esters that are then shuttled across the mitochondrial 
membranes by L-carnitine/acyl-L-carnitine translocase (CACT) (Bremer, 1983). Inside the 
mitochondrial matrix, acyl-L-carnitine is converted back to L-carnitine and long-chain FA by 
the enzyme CPT II. Thus, L-carnitine aids the import of long-chain FA to the mitochondria 
for ǃ-oxidation, which is the major provider of energy for muscle cells.  
In addition to its role in FA transport pathways, L-carnitine is also involved in the export of 
acetyl groups out of the mitochondria (Stephens et al., 2007). In the mitochondrial matrix, 
lumen of the endoplasmic reticulum and peroxisomes, L-carnitine acetyltransferase (CrAT; 
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EC 2.3.1.7) catalyses the reversible transfer of acetyl groups between acetyl-CoA and L-
carnitine (Ramsay et al., 2001). By catalysing its reaction in a reversible manner, CrAT 
regulates the cellular pool of CoA, which serves as a carrier of activated acetyl groups in the 
oxidation of energy metabolism substrates and in the synthesis of FA and lipids (Ramsay et 
al., 2001). Glucose metabolism pathways are also regulated through the homeostasis of the 
ratio of acetyl-CoA/CoA. An increase in this ratio is sensed by pyruvate dehydrogenase 
kinase, which phosphorylates and thereby leads to the inhibition of the pyruvate 
dehydrogenase complex (PDC), the key rate-limiting step in carbohydrate oxidation 
(Lopaschuk, 2001; Rebouche, 2004), with L-carnitine being a pivotal regulator of these 
pathways. For example, during high-intensity exercise, L-carnitine enters the CrAT-
catalysed reaction and buffers the excess acetyl groups formed. As a result, a pool of free 
CoA is maintained for the continuation of the PDC and citric acid cycle reactions (Stephens 
et al., 2007). It can be concluded that L-carnitine is important for the regulation of both long-
chain FA and carbohydrate metabolism. L-carnitine-dependent pathways are strongly 
involved in the regulation of the adaptive responses related to the overall homeostasis of 
cellular energy metabolism. 
2.2 The bioavailability of L-carnitine 
The homeostasis of L-carnitine (Fig. 2) is maintained through biosynthesis, efficient 
reabsorption in the kidneys and food intake, particularly from meat and dairy products 
(Rebouche, 2004). The physiological range of different L-carnitine concentrations in various 
tissues is maintained by complex transporter systems (Ramsay et al., 2001). The biosynthesis 
of L-carnitine from the amino acids lysine and methionine proceeds in the liver, kidney and 
testis, with Ǆ-butyrobetaine (GBB) being an intermediate precursor (Bieber, 1988). It has 
been estimated that in the case of a non-vegetarian diet, only about 25% of the necessary L-
carnitine is biosynthesised, and 75% is ingested from food (Longo et al., 2006). Interestingly, 
the blood plasma concentration in women is about 20% lower than in men (Cederblad, 
1976). Additionally, in vegetarians, the L-carnitine concentration in the blood serum is 20-
30% lower than that in the reference population (Delanghe et al., 1989). 
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Fig. 2. The body L-carnitine pools and turnover. 
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After oral intake, the absorption of L-carnitine proceeds by active transport and passive 
diffusion (Ramsay et al., 2001). It has been shown experimentally that the absolute 
bioavailability of L-carnitine after a peroral dose of 1-6 g was only 5-18%, while the intake of 
L-carnitine by food resulted in an absorption of up to 75% (Evans et al., 2003). When the 
peroral dose was higher than 6 g, a specific smell was noted, possibly due to an increased 
concentration of trimethylamine in sweat (Hathcock et al., 2006).  
Interestingly, the L-carnitine concentration that is required to support long-chain FA 
oxidation spans a wide range among different tissues of the same species and in the same 
tissue across species (Long et al., 1982; McGarry et al., 1983) because different tissues express 
different isoforms of CPT I, which are, in turn, differentially sensitive to L-carnitine. For 
example, the rat isoforms of CPT I in the liver (CPT IA) and muscle (CPT IB) have Km 
values for L-carnitine of 30 and 500 μM, respectively (McGarry et al., 1983). In the heart, 
both CPT I isoforms, CPT IA and CPT IB, are present, and as a result, the average Km for L-
carnitine in the heart is 200 μM (McGarry et al., 1983). Therefore, the liver is much less 
sensitive to lower L-carnitine concentrations than the muscles and the heart. Additionally, in 
cases of a reduced L-carnitine concentration, a compensatory increase in CPT I is observed 
(Uenaka et al., 1996). In a recent publication, it was demonstrated that systemic L-carnitine 
deficiency causes severe hypoglycaemia in mice (Kuwajima et al., 2007). Similarly, after 
treatment with sodium pivalate, glucose oxidation was increased in L-carnitine-deficient 
hearts (Broderick, 2006). Thus, the bioavailability of L-carnitine changes along with the 
amounts of its dietary intake, and its requirements could be different in different tissues, 
reflecting the energy needs under certain conditions. 
2.3 Effects of L-carnitine supplementation 
During the last decades, the intake of L-carnitine as a food supplement has become very 
popular even though scientific evidence of its efficacy is not always available. Undoubtedly, 
L-carnitine is effective for the treatment of inherited disorders related to functional 
anomalies in a specific organic cation/carnitine transporter (OCTN2), in drug-induced L-
carnitine deficiency and in cases of excessive excretion of L-carnitine because of renal 
tubular disorders and in patients on haemodialysis (Angelini et al., 2006; Fornasini et al., 
2007; Lheureux et al., 2005). The safety profile of L-carnitine allows its frequent use in 
cocktails of food additives that are aimed to increase the oxidation of FA to eliminate body 
fat and thus produce cosmetic effects. However, thus far, the body weight-reducing effect of 
L-carnitine supplementation has not been proven clinically (Saper et al., 2004). A similar 
situation is characteristic for the use of L-carnitine for improved physical activity. The 
ineffectiveness of L-carnitine might be related to its low bioavailability during normal 
homeostasis (Hathcock et al., 2006). As a result, additional L-carnitine does not reach the 
cellular mitochondria where it could bring about the desired effects and drive the processes 
of FA metabolism. Recent developments in the use of L-carnitine to stimulate the oxidation 
of FA are linked to novel approaches to increase the bioavailability of L-carnitine (Stephens 
et al., 2007). 
In addition to being an important cofactor for the L-carnitine mediated transport of long-
chain FA into the mitochondrial matrix, as a pharmacological agent, L-carnitine enhances 
the glycolytic processing of carbohydrates (Foster, 2004; Mingrone, 2004; Stephens et al., 
2007). The suggested mechanisms of pharmacological action of L-carnitine are increased 
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PDC activity, regulation of acetyl- and acyl-cellular trafficking and changes in the acetyl 
CoA/CoA ratio and expression of key glycolytic and gluconeogenic enzymes (Mingrone, 
2004; Uziel et al., 1988). L-carnitine also stimulates glucose oxidation in intact fatty acid-
perfused rat heart (Broderick, 2006). The beneficial effects of L-carnitine supplementation in 
animal models of diabetes also have been demonstrated (Malone et al., 1999; Malone et al., 
2006; Sena et al., 2008). L-carnitine supplementation is believed to be beneficial for diabetic 
patients (Mingrone, 2004). In type 2 diabetic patients, L-carnitine increases the amount of 
whole-body glucose utilisation and glucose oxidation (Capaldo et al., 1991; De et al., 1999). 
However, for use in the management of diabetic complications, L-carnitine is listed between 
antioxidants for which no established benefit has been found (Golbidi et al., 2011), and the 
effects of L-carnitine in healthy subjects or in type 2 diabetic patients are still controversial 
(Gonzalez-Ortiz et al., 2008). Nevertheless, additional intake of L-carnitine is recommended 
for diabetic patients with late complications (Poorabbas et al., 2007; Power et al., 2007).  
Because FA metabolism is the main source of energy for muscle cells, including 
cardiomyocytes, the effects of L-carnitine have been evaluated for the treatment of different 
cardiovascular diseases (Ferrari et al., 2004). The evidence for the cardioprotective 
effectiveness of L-carnitine is also not unambiguous. Treatment with L-carnitine was 
protective against ischemia-reperfusion injury (Cui et al., 2003), but another experimental 
study provided evidence that L-carnitine worsens ischemic injury under conditions where 
L-carnitine does not facilitate glucose metabolism (Diaz et al., 2008). For example, in the 
CEDIM 2 trial, L-carnitine therapy led to a reduction in early mortality without affecting the 
risk of death and heart failure at 6 months in patients with anterior acute myocardial 
infarction, resulting in a non-significant finding with respect to the primary end-point 
(Tarantini et al., 2006). 
Even though the clinical and experimental evidence for the effects of supplementary L-
carnitine intake are not always convincing, it is a very popular food additive due its safety 
profile, antioxidant-type activity and suggested effects on energy metabolism pathways. 
3. Metabolic consequences of pharmacologically decreased availability of L-
carnitine 
Mildronate (3-(2,2,2-trimethylhydrazinium)propionate dihydrate) (Fig. 3) represents the 
only pharmacological agent that effectively reduces L-carnitine concentration and in turn 
induces protective effects against diabetes and cardiovascular diseases. The mechanism of 
action of mildronate is believed to involve a decreased tissue concentration of L-carnitine 
(Dambrova et al., 2002), even though other possible interactions between mildronate and 
pathways of energy metabolism signalling cannot be excluded. 
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Fig. 3. Structural formulas or GBB (A), mildronate (B) and carnitine (C).  
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3.1 Inhibitory effect of mildronate on L-carnitine content 
Mildronate is known to be an inhibitor of L-carnitine biosynthesis (Simkhovich et al., 1988), 
its transport into tissues and its reabsorption in the kidney (Kuwajima et al., 1999). The Ki 
for GBB hydroxylase enzyme inhibition by mildronate has been determined to be 19 μM 
(enzyme prepared as described by (Tars et al., 2010)). The EC50 for OCTN2 inhibition by 
mildronate was calculated to be 21 μM (Grube et al., 2006). At a dose of 100 mg/kg, the 
mildronate concentration in rat blood plasma reached 20 μM after a single administration; 
however, after 3 days of repeated administration, the mildronate concentration remained at 
20 μM even 24 h after the last administration (Liepinsh 2006). Mildronate is actively 
transported into tissues by OCTN2 (Grigat et al., 2009), and the mildronate concentration in 
liver and heart reaches 500-1000 μM (Liepinsh et al., 2009a). Thus, mildronate concentrations 
are able to completely inhibit L-carnitine biosynthesis and substantially decrease L-carnitine 
transport into tissues and reabsorption in the kidneys. As a result, mildronate (100 mg/kg) 
induces a significant reduction of the L-carnitine concentration in blood plasma and 
different tissues by 60-70% (Liepinsh et al., 2009a). In our recent human study, it was shown 
that mildronate also decreases L-carnitine concentrations by 20% in healthy human non-
vegetarian volunteers (Liepinsh et al., 2011a). A less-pronounced effect of mildronate on L-
carnitine content in humans could be explained by meat consumption, which is the most 
important source of L-carnitine (Rebouche, 2004). Compared to a human non-vegetarian 
diet, in standard laboratory animal feed, the content of L-carnitine is very low (unpublished 
data). Overall, after long-term treatment, the plasma concentration of mildronate reaches a 
level that is able to induce changes in the homeostasis of L-carnitine. However, it must be 
noted that to our knowledge, an acute mildronate treatment does not induce any metabolic 
or gene expression changes, and therefore, long-term treatment (at least 10-14 days) is 
necessary to achieve regulatory effects. In addition, all changes induced by mildronate are 
highly related to the decrease in the L-carnitine concentration in tissues. The modulation of 
L-carnitine pathways by mildronate then changes the activity of cellular enzymes and 
receptor systems in a manner that could maintain sufficient energy metabolism and induce 
adaptive-like changes. 
By inhibiting the biosynthesis of L-carnitine, mildronate increases the concentration of its 
substrate, Ǆ-butyrobetaine (GBB, Fig. 3.), which is mostly known as a bio-precursor of L-
carnitine (Bremer, 1983). We have investigated the effects of mildronate administration (4-12 
weeks, 100 mg/kg) on both L-carnitine and GBB contents in rat plasma and tissues and have 
shown that in concert with a decrease in L-carnitine concentration, the administration of 
mildronate causes a significant increase in GBB concentration (Liepinsh et al., 2009a). There 
have been speculations regarding the cholinergic activity of GBB; however, only the methyl-
ester of GBB produces this activity (Dambrova et al., 2004). The physiological and 
pharmacological consequences of increased GBB concentration remain to be discovered. 
3.2 Metabolic changes in fatty acid metabolism 
3.2.1 The effects on CPT I and mitochondrial fatty acid metabolism 
Mildronate-decreased tissue L-carnitine concentrations induce changes in the energy 
metabolism pathways, especially in mitochondrial long-chain FA oxidation (Fig. 4). These 
changes are exclusively related to CPT I activity and FA transport into the mitochondria. If 
the L-carnitine content is lowered by mildronate treatment, a subsequent decrease in CPT I 
activity and a decreased CPT I-driven FA oxidation rate is observed (Kuka et al., 2011; 
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Simkhovich et al., 1988). Interestingly, due to the differences in L-carnitine content and the 
Km values of CPT I for L-carnitine, at least a 60-70% reduction in L-carnitine content in the 
heart is necessary to reduce CPT I-dependent long-chain FA transport and oxidation.  
Additionally, if the L-carnitine content is lowered significantly below the Km value of CPT I, 
a compensatory increase in CPT I expression is observed (Uenaka R 1996). After long-term 
mildronate treatment, a 2 to 2.5-fold increase in the expression of CPT IA and CPT IB was 
found in the heart and liver (Degrace et al., 2007; Liepinsh et al., 2008). However, the 
increase in CPT I protein expression cannot compensate for significantly reduced L-carnitine 
availability, and therefore, subsequent changes in metabolic pathways occur. Although the 
expression of CPT I after mildronate treatment is increased, the overall FA oxidation rate in 
mitochondria is decreased (Kuka, et al. 2011; Simkhovich et al., 1988).  
In a recent study, the effects of mildronate, L-carnitine and a combination of both substances 
on myocardial infarction were compared (Kuka et al., 2011). Mildronate treatment markedly 
decreased the L-carnitine concentration of the heart tissue and significantly decreased the 
infarct size. Administration of mildronate together with L-carnitine restored the L-carnitine 
concentration, and therefore, CPT I activity was similar to that in control samples; as a 
consequence, the infarct size was not reduced. Therefore, we conclude that the decrease of 
L-carnitine concentration is the main mechanism of action of mildronate, and this decrease 
is necessary to induce changes in cellular energy metabolism. 
3.2.2 The modulation of PPARs and fatty acid metabolism-related gene expression 
Peroxisome proliferator-activated receptors (PPARs) are central regulators of energy 
metabolism that mediate adaptive metabolic responses to increased systemic lipid 
availability following activation by the binding of endogenous or dietary lipids or lipid 
derivatives (Grimaldi, 2007; Sugden et al., 2009). Several genes that are induced by 
mildronate treatment, particularly CPT I (Degrace et al., 2007; Liepinsh et al., 2008), suggest 
PPARs as possible nuclear factors involved in the mildronate-induced effects on glucose and 
FA metabolism (Fig. 4). In a very recent study to elucidate the molecular mechanism of 
mildronate, PPAR-ǂ and PPAR-Ǆ nuclear content and the expression of glucose and FA 
metabolism genes were determined in obese Zucker rats (Liepinsh et al., 2011b). The hearts 
of obese Zucker rats had a significant impairment in the PPAR-ǂ system, and the response 
to increased FA and triglyceride (TG) was disrupted. Thus, the expression of PPAR-ǂ and its 
target genes in obese Zucker rat heart tissue was reduced compared to their expression in 
lean animals. Mildronate treatment restored the sensitivity of PPAR-ǂ, which is manifested 
as significantly increased nuclear expression of PPAR-ǂ in heart tissue and the expression of 
genes involved in FA metabolism. In cell culture, we found that mildronate and L-carnitine 
did not change PPAR activity in vitro. Thus, PPAR activation is instead induced as a result 
of a reduced FA oxidation rate and some FA accumulation. 
Interestingly, increased expression of FA metabolic genes, particularly CPT-I, did not 
compensate for a reduction in the L-carnitine content, and therefore, the CPT I-dependent 
FA oxidation rate in heart tissue was significantly reduced. However, PPAR-ǂ activation 
also induces genes that are involved in intra-mitochondrial FA ǃ-oxidation. Thus, 
mildronate treatment could stimulate mitochondrial ǃ-oxidation of FA transported into the 
mitochondria by CPT I (mildronate induces partial reduction in CPT I activity) and 
carnitine-acylcarnitine transport system. This could be another mechanism to protect the 
mitochondria from lipid overload and the accumulation of FA in mitochondria. To test this 
hypothesis, mitochondrial respiration measurements were performed on energy substrates 
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like palmitoyl-CoA and palmitoyl-L-carnitine. CPT I-dependent mitochondrial oxidation of 
palmitoyl-CoA was reduced in mildronate-treated rat hearts, while palmitoyl-L-carnitine 
oxidation in mildronate-treated heart mitochondria was even faster than in the control 
group (unpublished data). In contrast, the expression of PPAR-ǂ and target genes in the 
liver of obese Zucker rats was not significantly affected by treatment. The effects of 
mildronate on PPAR-Ǆ and PPAR-ǅ and the expression of their target genes are rather 
unclear and should be clarified in future studies. In conclusion, mildronate-dependent gene 
expression is, to some extent, dependent on the activation of PPAR-ǂ in heart tissue but not 
in liver tissue. 
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Fig. 4. The effects of pharmacologically decreased availability of L-carnitine on PPAR-ǂ 
activity and fatty acid metabolism pathways. The red arrows indicate mildronate-induced 
changes; green arrows indicate stimulating effects of PPAR-ǂ.  
3.2.3 Metabolic flexibility and protection against lipid overload 
Healthy subjects, depending on the availability of glucose or FA, are able to switch 
appropriately between the available energy substrates (Fig. 5A). At a postprandial state, the 
glucose and insulin concentrations are increased, and glucose oxidation dominates over FA 
oxidation.  In contrast, in a fasted state, the glucose concentration is significantly lower, and 
energy metabolism is switched to FA. As shown in Fig. 5B, in obese subjects, lipid overload 
induces a metabolic inflexibility that is characterised by the reduced ability of cells to 
appropriately move between energy metabolism substrates (Larsen et al., 2008). Thus, an 
increase in circulating lipids stimulates FA influx into the mitochondria (Koves et al., 2008b; 
Petersen et al., 2004). Then, the increased concentration of long-chain FA and intermediates 
of FA metabolism, in particular acetyl-CoA, mediates the inhibition of the PDC and CPT I 
activity and induces the impairment of the citric acid cycle and respiratory chain functions 
(Koves et al., 2008b; Wang et al., 2007). These changes result in a pathologically decreased 
oxidation rate of both glucose and FA and deteriorate the mitochondrial capacity to produce 
ATP (Kelley et al., 2002). Therefore, lipid overload-induced metabolic inflexibility and 
lipotoxicity is primarily associated with FA accumulation in the mitochondria. 
Mildronate treatment prevents lipid overload by decreasing the L-carnitine content in 
tissues and subsequently decreasing CPT I-mediated long-chain FA transport and 
pathological accumulation in the mitochondria (Asaka et al., 1998; Kirimoto et al., 1996). In 
obese Zucker rats, mildronate induced a moderate increase in the FA and TG 
concentrations, and it significantly improved insulin sensitivity and reduced blood glucose 
and insulin concentrations (Fig. 5C) (Liepinsh et al., 2011b). Thus, mildronate treatment, by 
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decreasing L-carnitine content, improves metabolic flexibility and adaptive responses to 
hyperglycaemia- and hyperlipidaemia-induced metabolic disturbances. 
 
 
Fig. 5. Metabolic flexibility, inflexibility and mildronate treatment induced protection 
against lipid overload.  
3.2.4 Comparison of mildronate to other inhibitors of fatty acid oxidation 
Different approaches are used to inhibit FA oxidation and to switch energy metabolism 
from FA to glucose oxidation (Table 1). The most similar to the mildronate mechanism of 
action is the direct inhibition of CPT I or targeting malonyl-CoA, which is a potent 
endogenous inhibitor of CPT I (Anderson et al., 1995; Cuthbert et al., 2005). Because CPT I is 
the rate-limiting enzyme in FA oxidation, the inhibition of CPT I is an effective way to 
achieve a decrease in the long-chain FA oxidation rate. Several irreversible and reversible 
inhibitors of CPT I, such as etmoxir and teglicar, were synthesised and tested experimentally 
(Table 1). A significant myocardial infarction-lowering effect for etmoxir was demonstrated; 
however, its toxicity strongly limits its usage in clinic. Teglicar, both in vitro and in animal 
models, reduces gluconeogenesis and improves glucose homeostasis (Table 1) (Conti et al., 
2011). Another approach is to inhibit malonyl-CoA decarboxylase, an enzyme that degrades 
malonyl-CoA to acetyl-CoA. The inhibition of this reaction by selective inhibitors leads to 
the accumulation of malonyl-CoA which inhibits CPT I and related FA oxidation. The 
inhibitors of CPT II have also been considered to be potentially useful for the treatment of 
type 2 diabetes (Rufer et al., 2009). Overall, the direct inhibition of CPT I or CPT II as well as 
an increase in malonyl-CoA and reduction in L-carnitine concentrations are similarly 
effective ways to target CPT I-dependent FA oxidation As a result, cardiac metabolism is 
switched from FA to glucose oxidation. 
In contrast, trimetazidine and ranolazine inhibit 3-ketoacyl coenzyme-A thiolase, which 
catalyses the last step in mitocondrial FA ǃ-oxidation. A potential benefit offered by 
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trimetazidine and ranolazine in myocardial dysfunction is the ability to increase the 
utilisation of glucose and lactate, improving oxygen consumption of the myocardium. 
Overall, free FA inhibitors effectively act as metabolic modulators in the protection of 
ischemic myocardium both in non-diabetic and diabetic subjects. 
 
Name 
Mechanism of 
action 
Effect on 
myocardial 
infarction 
Effect on 
blood 
glucose 
metabolism
Benefit against 
diabetes 
complications 
Literature 
Mildronate 
Lowered L-
carnitine conc. 
and CPT I 
dependent FA 
oxidation 
↓ ↑ + 
(Liepinsh 
et al., 
2009b; Sesti 
et al., 2006) 
Trimetazidine 
Inhibition of 3-
KAT in 
mitochondrial 
FA ǃ-oxidation 
↓ ↑ + 
(Monti et 
al., 2006; 
Mouquet et 
al., 2010) 
Ranolazine 
Inhibition of 3-
KAT in 
mitochondrial 
FA ǃ-oxidation 
↓ ↑ + 
(Hale et al., 
2008; 
Morrow et 
al., 2009) 
Etmoxir 
Inhibition of CPT 
I and dependent 
FA oxidation 
↓ 
 
↑ ? 
(Gunther et 
al., 2000; 
Wolf et al., 
1988) 
Teglicar 
Inhibition of 
liver CPT IA and 
dependent FA 
oxidation 
? ↑ ? 
(Conti et al., 
2011) 
3-KAT – 3-ketoacyl coenzyme-A thiolase, FA – fatty acids, CPT I – L-carnitine palmitoyl transferase, ↑ – 
stimulate, ↓ – decrease, + – beneficial effect, ? – under investigation. 
Table 1. Comparison of mildronate to other inhibitors of fatty acid oxidation.  
3.3 Metabolic changes in glucose metabolism 
3.3.1 Switch to glucose metabolism 
It is generally accepted that better survival of ischemic myocardium cells can be achieved by 
stimulating glucose oxidation, either directly or secondarily, to partially inhibited FA 
oxidation (Lopaschuk, 2001). The beneficial effects of metabolic modulators in cardiac tissue 
are based on the increased efficiency of the obtained ATP per mole of oxygen for glucose 
oxidation compared to FA oxidation and, more importantly, the increased coupling of 
glycolysis to glucose oxidation resulting in a net reduction of the proton burden in the 
ischemic tissue (Schofield et al., 2001; Taegtmeyer et al., 1998). Moreover, insulin resistance 
and lowered glucose uptake and oxidation have been associated with the progression of 
cardiovascular pathologies such as coronary heart disease and heart failure (Kamalesh, 2007; 
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Taegtmeyer et al., 1998). A shift of the energy substrate preference from FA oxidation to 
glucose oxidation was suggested as a basis for the cardioprotective effects of mildronate 
long before it was demonstrated experimentally (Asaka et al., 1998; Dambrova et al., 2002). 
Indeed, the reduction of L-carnitine content by mildronate treatment leads to a decrease in 
the CPT I-dependent FA oxidation rate in mitochondria, and in turn, due to a Randle cycle, 
a substantial increase is expected in the rate of glucose uptake, as was found in mouse hearts 
after mildronate treatment (Liepinsh et al., 2008). Thus, in cases of partially decreased FA 
oxidation, changes in glucose metabolism could play a compensatory role. In contrast to 
mouse and diabetic rat models, where a significant blood glucose-lowering effect was 
observed, the glucose concentration was not significantly decreased in rats treated with 
mildronate at doses up to 400 mg/kg (Liepinsh et al., 2009a). These results suggest that 
mildronate treatment does not directly stimulate but rather facilitates glucose metabolism 
and that the effect of mildronate strongly depends on substrate availability and energy 
requirements. 
3.3.2 Effects on insulin signalling 
Insulin is the major regulator of glucose homeostasis in the body. The insulin signalling 
pathway is responsible for controlling substrate preference in the heart, muscles and 
adipose tissues. Insulin stimulates myocardial glucose uptake and accelerates glucose 
oxidation (Benecke et al., 1993). Both in non-diabetic and diabetic animals, mildronate 
treatment significantly facilitates insulin-dependent glucose uptake and metabolism (Fig. 6). 
At the same time, mildronate, which decreases the blood glucose concentration in mice and 
diabetic rats, usually does not affect plasma insulin and C-peptide levels (Liepinsh et al., 
2008; Liepinsh et al., 2009b). In addition, in study in Zucker rats mildronate along with 
decrease in glucose concentration also decreased pathologically elevated insulin 
concentration in fed Zucker rats (Liepinsh et al., 2011b). Moreover, mildronate induces a 
statistically significant 35% increase in insulin-stimulated glucose uptake in isolated mouse 
hearts (Liepinsh et al., 2008). Mildronate action could be explained by specific insulin 
pathway-related gene expression. During insulin-stimulated conditions, glucose transport 
by GLUT 4 is the rate-limiting step for glucose uptake in muscles and the heart. In 
genetically manipulated mice overexpressing GLUT 4, improvement in both glucose 
tolerance and insulin action were noted (Hansen et al., 1995). Mildronate treatment induces 
an increase in GLUT 4 protein expression in heart tissues, which explains the increase in 
insulin-stimulated glucose uptake. 
The important intracellular regulators of aerobic oxidation of glucose are the enzymes of the 
PDC, which links the glycolysis metabolic pathway to the mitochondrial citric acid cycle 
(Fig. 6). A significant 2-fold increase in the expression of both PDC enzymes, E1/E2, in 
mildronate-treated mouse hearts compared with non-treated controls was observed. In 
addition, in several studies, a decrease in lactate concentration in ischemic hearts of 
mildronate-treated animals has been noted, which indicates that long-term mildronate 
treatment not only facilitates glucose uptake but also enhances the aerobic oxidation of 
glucose (Asaka et al., 1998; Hayashi et al., 2000b; Liepinsh et al., 2011b). Besides the direct 
effects of insulin on glucose homeostasis, stimulation of the insulin receptor leads to the 
activation of signalling pathways such as the phosphatidylinositol-3-kinase and the 
mitogen-activated protein kinase cascades, which are involved in cardioprotection from 
reperfusion injury (Jonassen et al., 2001; Youngren, 2007). Overall, the observed increase of 
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insulin receptor sensitivity could be important for the manifestation of the cardioprotective 
and antidiabetic effects of the mildronate treatment. 
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Fig. 6. The effects of pharmacologically decreased availability of L-carnitine on glucose 
metabolism. The red arrows indicate mildronate-induced changes; green arrows indicate 
stimulating effects of insulin.  
4. Pharmacological effects of decreased availability of L-carnitine 
4.1 Effects on myocardial infarction 
Mildronate is primarily known as a cardioprotective drug, the mechanism of action of which 
is based on a decrease of L-carnitine concentration, regulation of energy metabolism and 
enhancement of preconditioning-like adaptive responses (Dambrova et al., 2002). In the past 
10 years, cardioprotective effects of mildronate have been extensively studied in different 
models of heart infarction and heart failure (Hayashi et al., 2000b; Liepinsh et al., 2006; Sesti 
et al., 2006; Vilskersts et al., 2009a). It was shown that long-term treatment with mildronate 
preserved ATP production by optimisation of energy metabolism. Then, a significant 
reduction of infarct size was shown in an isolated heart infarction model both in vitro 
(Liepinsh et al., 2006) and in vivo (Sesti et al., 2006). In addition, mildronate was recently 
demonstrated to be cardioprotective in diabetic Goto-Kakizaki (G-K) rats, where besides the 
glucose-lowering effect, mildronate treatment at doses of 100 and 200 mg/kg decreased the 
infarct size by 30% (Liepinsh et al., 2009b). Overall, mildronate treatment effectively reduces 
myocardial infarction in diabetic GK and non-diabetic Wistar rats. 
Treatment with mildronate did not have a significant effect on haemodynamic parameters 
either before or during ischemia-reperfusion, indicating that the observed effects on infarct 
size are not related to changes in the cardiac workload. This result gives evidence that 
mildronate primarily acts as metabolic regulator and provides opportunities to effectively 
combine mildronate with agents affecting haemodynamic parameters. In animal studies, 
mildronate is combined with orotic acid, which is also known as an energy metabolism-
influencing metabolite (Vilskersts et al., 2009a). Mildronate possesses additive 
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pharmacological effects with orotic acid, and mildronate orotate might be considered a 
powerful therapeutic agent facilitating recovery from ischemia-reperfusion injury. In the 
same study, we found that the administration of mildronate and its orotate salt decreased 
the duration and incidence of arrhythmias in experimental arrhythmia models. 
4.2 Heart failure 
The effects of mildronate on haemodynamics, cardiac hypertrophy and metabolic 
consequences in rats after coronary artery ligation were also studied. Mildronate induces 
significant attenuation of the development of left ventricular (LV) hypertrophy and of 
increased LVEDP. These results suggest that mildronate improved LV hypertrophy and LV 
dysfunction in rats with heart failure induced by myocardial ischemia (Nakano et al., 1999). 
In a similar study performed by Hayashi et al., the effects of mildronate were examined in 
rats with congestive heart failure following myocardial infarction (Hayashi et al., 2000b). A 
survival study was conducted for 6 months, and ventricular remodelling, cardiac function, 
and myocardial high-energy phosphate levels after treatment for 20 days were measured. 
Mildronate prolonged survival, prevented expansion of the left ventricular cavity 
(ventricular remodelling), attenuated the rise in right atrial pressure and augmented cardiac 
functional adaptability against an increased load. Additionally, an improved myocardial 
energy state in mildronate-treated rats was observed. A different study by the same authors 
demonstrated that the mechanisms of mildronate action in heart failure are based on the 
amelioration of [Ca2+]i transients through an increase in SR Ca2+ uptake activity (Hayashi 
et al., 2000a). 
Several clinical studies evaluated the efficacy of mildronate in the complex therapy of 
chronic heart failure (CHF). Statsenko, ME et al. evaluated the clinical efficacy of mildronate 
in addition to basic therapy in patients with CHF and type 2 diabetes mellitus (DM2) during 
the postinfarction period (Statsenko et al., 2007). The subjects were 60 II to III NYHA CHF 
patients aged 43 to 70 years who were also suffering from DM2. The patients were observed 
during the early postinfarction period (weeks 3 to 4 from the onset of myocardial infarction). 
The use of mildronate in addition to basic therapy was associated with a more evident 
decrease in CHF functional class, an increase in 6-min walking test distance, a tendency 
towards normalisation of diastolic heart function and an increase in LVEF. Also, in a recent 
study, the advantage of treatment with mildronate (1 g/day) as a corrector of metabolism in 
combination with standard therapy for the exercise tolerance of patients with CHD over 
treatment with a placebo in combination with standard therapy was noted (Dzerve et al., 
2010). The overall conclusion from clinical studies is that the use of mildronate in basic 
therapy favours the normalisation of vegetative homeostasis and improves the quality of 
life. 
4.3 Metabolic syndrome and diabetes 
The effects of mildronate on glucose metabolism and its benefits in the treatment of 
diabetes have been proven experimentally only during the last decade, even though they 
had been suggested previously (Dambrova et al., 2002). This delay could be because 
mildronate at doses up to 400 mg/kg did not affect the blood glucose concentration in 
non-diabetic rats. Mildronate reduced blood glucose in Wistar rats only at a dose of 800 
mg (Degrace et al., 2007). The possible anti-diabetic effects of mildronate were then 
examined in an experimental model of type 2 diabetes in GK rats (Liepinsh et al., 2009b). 
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The main finding of this study was that decreased L-carnitine availability leads to fed and 
fasted blood glucose concentration-lowering effects without increasing the insulin 
concentration in diabetic GK rats. As mentioned before, mildronate also induced 
cardioprotective effects in GK rat hearts. At the end of an 8-week treatment, the necrosis 
zone in mildronate-treated diabetic rat hearts was significantly decreased by 30%. Overall, 
these findings directly indicate that mildronate treatment could be beneficial in diabetes 
patients with cardiovascular diseases. Furthermore, mildronate effectiveness was tested in 
rats with streptozotocin-induced diabetes mellitus (Sokolovska et al., 2011). As expected, 
long-term mildronate treatment caused a significant decrease in the mean blood glucose 
and glycated haemoglobin (HbA1c) concentrations in streptozotocin-treated rats. Thus, 
the glucose-lowering effects were shown experimentally both in type 1 and type 2 
diabetes mellitus.  
In a recent study, the effects of mildronate treatment were compared to the effects of 
metformin treatment in obese Zucker rats (Liepinsh et al., 2011). In this study, mildronate 
treatment, to the same extent as metformin, significantly reduced the blood glucose 
concentration in the fed and fasted states and increased the insulin concentration in obese 
Zucker rats. In addition, several effects caused by the combination of mildronate and 
metformin treatment were additive or even synergistic. An additive effect in an oral 
glucose tolerance test and in the reduction of insulin concentration was observed. 
Moreover, treatment with the combination of both drugs increased liver glycogen content, 
suggesting a significant improvement in liver insulin sensitivity. Thus, the additional 
increase in body insulin sensitivity is a benefit of treatment with this combination. These 
changes may be explained by an increase in the expression of glucose metabolism genes, 
such as Glut-1, HK-2 and, in particular, GLUT 4.  Furthermore, treatment with mildronate 
or metformin alone did not significantly change the weight gain of obese Zucker rats. In 
contrast to monotherapy, treatment with the combination of mildronate and metformin 
induced a significant reduction in weight gain and especially fat mass, which was 
decreased by 47% in combination-treated rats. Thus, the combination therapy of 
mildronate with metformin could have a potential therapeutic value in the treatment of 
obese patients with type 2 diabetes. Additionally, one of the well-known side effects of 
metformin is related to an increased lactate level. In this study, mildronate treatment 
separately or in combination with metformin reduced the lactate concentration in obese 
Zucker rat plasma, and therefore, mildronate used in combination could reduce the risk of 
metformin-induced lactate acidosis. 
4.4 Diabetes complications 
Mildronate treatment induces protective effects not only in the heart but also in other 
tissues. Vilskersts et al. demonstrated that chronic treatment with mildronate at a dose of 
100 mg/kg significantly reduced the size of atherosclerotic plaques in the aortic roots and in 
the whole aorta in apoE/LDLR(-/-) mice (Vilskersts et al., 2009b). The effect of long-term 
treatment with mildronate on the functional manifestation of metabolic disturbances and 
diabetes-induced complications in diabetic animals was also studied (Liepinsh et al., 2009b). 
The contractile responsiveness to phenylephrine was significantly enhanced in the aortas of 
GK rats, and this hypersensitivity was normalised by mildronate at a dose of 200 mg/kg. 
The functional impairment of coronary arteries characterised by significantly lower 
coronary flow was observed in isolated GK rat hearts compared to those of Wistar rats. 
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After treatment by mildronate, coronary flow was significantly increased, indicating that 
long-term treatment with mildronate prevents endothelial dysfunction in animals with type 
2 diabetes. 
Peripheral neuropathy characterised by abnormality in the thermal pain threshold of 
diabetic GK rats was associated with the development of diabetes (Ueta et al., 2005). The loss 
of thermal response is dependent on the severity and duration of hyperglycaemia and is 
also a characteristic diabetic complication in the clinic. Long-term mildronate administration 
both controlled hyperglycaemia and prevented diabetic neuropathy. It is very likely that by 
influencing energy metabolism, mildronate reduces neuropathy in type 2 diabetes animals.  
An open randomised trial in diabetic patients investigated 70 matched patients with type 2 
diabetes mellitus and sensomotor neuropathy; the effectiveness of mildronate was evaluated 
for 3 months in addition to basic therapy (Statsenko et al., 2008). Mildronate administration 
did not influence glucose and Hb1Ac concentration, but it significantly improved the clinical 
condition of the study group patients vs. the controls by neuropathy and symptoms count 
scales, electrophysiological properties of the nerve fibres and optimisation of oxygen tissue 
balance. Overall, mildronate is suggested for the treatment of diabetes at a dose of 1 g/day 
as an addition to standard therapy. 
5. Conclusion 
In conclusion, a mildronate-induced decrease in L-carnitine concentration leads to a partial 
reduction in FA oxidation and shifts energy metabolism from free FA towards 
predominantly glucose utilisation by the myocardium to increase the effectiveness of ATP 
generation. Long-term pharmacologically decreased availability of L-carnitine induces 
adaptive effects by causing changes in FA and glucose metabolism-related gene expression, 
which are beneficial in the treatment of heart diseases and diabetes. The L-carnitine 
homeostasis is a valuable target for the regulation of energy metabolism pathways and 
treatment of metabolic diseases.  
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